Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Illumina, Inc. (NASDAQ:ILMN ) Evercore ISI HealthCONx Conference November 29, 2022 11:20 AM ET Company Participants Dr. Alex Aravanis - CTO Salli Schwartz - VP, IR Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Okay. Thanks, everyone, for joining us this morning.

Illumina, Inc. (ILMN) Presents at Evercore ISI HealthCONx Conference (Transcript)

MENLO PARK, Calif.--( BUSINESS WIRE )--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced findings from a fundamental substudy of the Circulating Cell-free Genome Atlas (CCGA; NCT02889978) study, demonstrating that methylation had the most promising combination of cancer detection and prediction of cancer signal origin when compared with other evaluated approaches. This is the first rigorous and systematic comparison of various genomic measures from circulating cell-free DNA (cfDNA) for multi-cancer early detection (MCED) testing, and the largest comprehensive genome-wide comparison of cfDNA approaches. Findings were published online in Cancer Cell in a manuscript titled “Evaluation of Cell-Free DNA Approaches for Multi-Cancer Early Detection.”

GRAIL CCGA Discovery Results Published in Cancer Cell Reveal Methylation as Promising DNA Hallmark for Multi-Cancer Early Detection

Illumina Inc said on Monday it was cutting 5% of its global workforce to realign its operating expenses as stubborn inflation and a strong dollar weigh on the genetic sequencing equipment maker's business.

Illumina cuts 5% of its workforce

Delays in instruments and consumables purchases, negative foreign exchange impact and consumables inventory deleveraging are expected to impede growth in the rest of 2022 for Illumina (ILMN).

Illumina (ILMN) Q3 Earnings Beat Estimates, '22 View Slashed

Illumina, Inc. (NASDAQ:ILMN ) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Francis deSouza - President & Chief Executive Officer Joydeep Goswami - Chief Strategy & Corporate Development Officer, Interim Chief Financial Officer Conference Call Participants Dan Brennan - Cowen Vijay Kumar - Evercore ISI Dan Arias - Stifel Puneet Souda - SVB Securities Julia Qin - JPMorgan David Westenberg - Piper Sandler Michael Ryskin - Bank of America Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley Dan Leonard - Credit Suisse Patrick Donnelly - Citi Luke Sergott - Barclays Jack Meehan - Nephron Research Operator Good day, ladies and gentlemen and welcome to the Third Quarter 2022 Illumina Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Illumina, Inc. (ILMN) Q3 2022 Earnings Call Transcript

Illumina (ILMN) delivered earnings and revenue surprises of 17.24% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Surpasses Q3 Earnings and Revenue Estimates

Illumina stock crumbled late Thursday after the company offered a lighter-than-expected outlook for full-year earnings. The post Illumina Plummets On Light Earnings Guidance Despite Quarterly Beat appeared first on Investor's Business Daily.

Illumina Plummets On Light Earnings Guidance Despite Quarterly Beat

Revenue of $1.12 billion for Q3 2022, up 1% from Q3 2021, and up 3% on a constant currency basis GAAP diluted loss per share of $(24.26) for Q3 2022, compared to GAAP diluted earnings per share of $2.08 for Q3 2021; GAAP diluted loss per share for Q3 2022 includes goodwill impairment of $3.91 billion related to the GRAIL segment Non-GAAP diluted earnings per share of $0.34 for Q3 2022, compared to non-GAAP diluted earnings per share of $1.45 for Q3 2021 Expect full year revenue for fiscal year 2022 to be flat to 1% higher compared to fiscal year 2021, primarily reflecting year-to-date growth in sequencing consumables revenue, largely offset by a fourth quarter decline in select research project sample volume; delayed purchases ahead of the upcoming availability of NovaSeq X and from customer inventory and capital management; and incremental foreign exchange headwinds Expect GAAP diluted loss per share of $(26.56) to $(26.41) for fiscal year 2022, which includes goodwill impairment of $3.91 billion related to the GRAIL segment Expect non-GAAP diluted earnings per share of $2.35 to $2.50 for fiscal year 2022 SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the third quarter of fiscal year 2022, which include consolidated financial results for GRAIL. "Our third-quarter results were in line with our expectations, with traction across our portfolio offset by challenging macroeconomic dynamics that we expect will continue into 2023," said Francis deSouza, Chief Executive Officer.

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2022

Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Illumina (ILMN) Ahead of Earnings?

Twist Bioscience Corp

Twist Bioscience and Illumina Partner to Produce Robust Exome Panel to Advance Research

Panel leverages precision metagenomics to transform testing for urinary tract infections Newest kit follows recent launch of panel testing for 66 viral pathogens that pose persistent threats to global public health SAN DIEGO , Nov. 1, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new research test for genitourinary pathogen and antimicrobial resistance (AMR) identification. The Illumina Urinary Pathogen Infectious Disease/Antimicrobial Resistance (ID/AMR) Panel (UPIP) applies precision metagenomics to detect and quantify pathogens, including those that are drug resistant that cause complicated and recurrent urinary tract infections (UTIs).

Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States

Bionano Genomics

Enphase Energy

Elbit Systems

ServiceNow

ON Semiconductor

Shockwave Medical

It's true that the troika of Microsoft (NASDAQ: MSFT ), Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ), and Meta (NASDAQ: META ), much loved by the Street for the decade that ended in mid-2021, reported disappointing third-quarter results. Once viewed as beyond reproach by most, those three stocks are now being shunned and scorned by the “smart money.

Ranking 7 Top Tech Stocks to Buy From Biggest to Smallest

The extended lockdown issues in limited geographies, including Greater China, where Illumina (ILMN) has extensive business, are expected to have adversely impacted its top line during the third quarter.

What's in the Cards for Illumina (ILMN) in Q3 Earnings?

A few months ago, gene sequencing juggernaut Illumina Inc. ( ILMN , Financial) seemed like it was well on its way to becoming a fallen giant. Amid flagging growth, the company had jumped the gun by re-acquiring Grail, a cancer testing startup that it had previously spun off in 2016, before securing regulatory approval in the EU.

Illumina Is Critically Undervalued

Illumina is the dominant player in gene sequencing.

This Growth Stock Rose Last Week. Is It Still a Buy?

Transformative alliance will help advance the World Health Organization's strategy to end the global TB epidemic by 2035 SAN DIEGO , Oct. 18, 2022 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics company, today announced a partnership to accelerate progress to end tuberculosis (TB) worldwide. The partnership will expand capabilities for countries most impacted by tuberculosis to more effectively detect and combat multidrug-resistant TB (MDR-TB).

Illumina and GenoScreen Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis

SAN DIEGO , Oct. 17, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it will host its second annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:30 am Pacific Time (12:30 pm Eastern Time), Friday, October 28, 2022. Francis deSouza, President and Chief Executive Officer, Aimee Hoyt, Chief People Officer, John Frank, Chief Public Affairs Officer, and Sharon Vidal, Head of Corporate Social Responsibility, will be joined by Salli Schwartz, Vice President of Investor Relations for a presentation, fireside chat, and Q&A session for investors, analysts, and other interested parties regarding Illumina's ESG strategy and action plans.

Illumina to Host Second Annual Virtual ESG Investor Event on Friday, October 28, 2022

GRAIL and Carrum Health Partner to Include Galleri® as Part of Comprehensive Cancer Care Offering to Employers

Zimmer Biomet Hlds

Zoetis

Broader market volatility and aggressive posturing by the Federal Reserve (Fed) have had market participants searching for safe havens.

Where to invest in Q4 2022? Morningstar's top picks

Aims to improve efficiency of pharma pipelines by leveraging industry-leading ability to identify genetic variants that contribute to human disease SAN DIEGO , Oct. 11, 2022 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a strategic research collaboration with AstraZeneca, a global, science-led biopharmaceutical company, to accelerate drug target discovery by combining their strengths in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise. The collaboration will evaluate whether a combined framework of these technologies can increase the yield and confidence of target discovery to find promising drugs based on human omics insights.

Illumina Launches Strategic Research Collaboration with AstraZeneca to Accelerate Drug Target Discovery

There is more to the comparison, and in the sections below, we discuss why we believe ILMN stock will offer better returns than TMO stock in the next three years.

After A 40% Fall This Year Illumina Stock Is A Better Pick Over Its Peer

SAN DIEGO , Oct. 6, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2022 following the close of market on Thursday, November 3, 2022.  On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, Chief Executive Officer, and Joydeep Goswami, Chief Strategy and Corporate Development Officer and Interim Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Illumina to Announce Third Quarter 2022 Financial Results on Thursday, November 3, 2022

The shares of Illumina, Inc. (NASDAQ:ILMN) got a kick from this week's broad-market rally, surging 9.5% on Tuesday to mark its biggest one-day jump since January.

Technical Trouble Haunts This Medtech Name

Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused

Is Illumina Still the Gamechanger in Genomics Sequencing?

New sequencing technologies and capabilities will accelerate the genomic discoveries and clinical insights needed to transform human health Revolutionary NovaSeq X Series sets new benchmark for speed, scale, accuracy, and sustainability SAN DIEGO , Sept. 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced multiple breakthrough sequencing innovations at its inaugural Illumina Genomics Forum: The launch of NovaSeq™ 6000 Dx as the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer, delivering the highest standards of compliance and driving actionable insights for patient care.

News for Illumina Stock (ILMN)